ManagedCareHemo.com Presents Cases in Cost Optimization and Care Coordination for Managed Care and Specialty Pharmacy
Jointly provided by
National Hemophilia Foundation    Medical Education Resources   
This activity is supported by independent educational grants from BioMarin, CSL Behring, Sanofi Genzyme, Takeda, and uniQure, Inc.

ManagedCareHemo.com Presents: Cases in Cost Optimization and Care Coordination for Managed Care and Specialty Pharmacy

Live Webcasts Complete! On-demand CE Archive Coming Soon

Until then, review the CE Primer to brush up on the latest in hemophilia treatment

Start now at: ManagedCareHemo.com/ClinicalPrimer
LEARN ABOUT
  • Recently approved and emerging hemophilia treatment options
  • Hemophilia-related complications associated with inhibitor development
  • Processes to improve communication and collaboration with hemophilia treatment centers (HTCs)
EXPERT FACULTY PRESENTERS
Marla Feinstein, PhD, MPH
Senior Policy & Healthcare Analyst
National Hemophilia Foundation 		John Fox, MD, MHA
Chief Boundary Spanner
Foxworthy Healthcare Consulting, LLC
James T. Kenney, RPh, MBA
Founder and President
JT Kenney, LLC 		Mark T. Reding, MD
Associate Professor of Medicine
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
TARGET AUDIENCE
  • This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, specialty pharmacists, care managers, registered nurses, and other managed care and payer organization professionals.
PROGRAM OVERVIEW

Hemophilia presents a unique challenge for managed care organizations and payer professionals: a disease with low incidence that is associated with high costs due to a significant need for health care resources. Successful management of hemophilia often depends on highly specialized, coordinated multidisciplinary care among providers, patients, and payers. To effectively address the clinical and administrative barriers to optimal hemophilia management, managed care and specialty pharmacy professionals require comprehensive education that increases knowledge and competence in several key areas. This program will demonstrate the importance of a well-coordinated patient management effort, the most cost-effective ways of using available treatments, and the importance of collaboration among all stakeholders, which includes leveraging the success of the comprehensive care model utilized by HTCs.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Describe recent insights into the safety, efficacy, and unique attributes of recently approved and emerging hemophilia treatment options.
  • Review alignment of recently approved therapies in the current hemophilia treatment algorithm.
  • Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences.
  • Apply processes for managed care and specialty pharmacy professionals to improve communication and collaboration with HTCs.
AGENDA
5 Minutes Opening Comments/Overview
James T. Kenney, RPh, MBA

20 Minutes Current Managed Care and Special Pharmacy Strategies for Cost-Effective Hemophilia Care
John Fox, MD, MHA

50 Minutes Hemophilia Case Scenarios and Follow-up Panel Discussions
James T. Kenney, RPh, MBA
Mark T. Reding, MD
John Fox, MD, MHA

15 Minutes Audience Question and Answer Session
Key Takeaways and Closing Comments

ACCREDITATION INFORMATION

Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 1.5 contact hours of continuing nursing education.
Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.5 contact hours.

Pharmacy Credit
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: 0816-9999-20-168-L01-P
This activity is certified as knowledge-based CPE.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.